secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2026-06-15T20:35:19+00:00
Accession:  0001628280-26-043232
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen FY2026 net loss $69.7M; PALISADE-4 topline results expected June 2026
------------------------------------------------------------------------------

- Net loss of $69.7M for FY ended March 31, 2026, vs $51.4M prior year; R&D expense $55.0M.
- Cash and marketable securities $45.4M; management expects runway into 2027.
- Completed randomized portion of PALISADE-4 Phase 3 trial of fasedienol for social anxiety disorder; topline results expected in June 2026.
- Received FDA 'Study May Proceed' letter for refisolone IND for menopausal hot flashes.
- Appointed new CMO (Dr. Angel Angelov), CFO (Nick Tressler), and Chief Corporate Development Officer (Elissa Cote).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000162828026043232/0001628280-26-043232-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000162828026043232/vtgn-20260615.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-043232

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer